Three major health care policy issues to watch in 2025

Taking stock of the drug industry, from the lab to the medicine chest

December 16, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Christine Kao/STAT STAT+ | Three major health care policy issues to watch in 2025 STAT 3 to Watch Series looks at health care policy under a Trump administration: Medicaid cuts, Affordable Care Act premium subsidies, and Medicare reforms. By John Wilkerson STAT+ | Feds threaten Sanofi with sanctions over plan to change payment terms for a federal drug discount program Sanofi insisted that its "credit model" will bring transparency by identifying potential duplicate discounts and prevent illegal diversion. By Ed Silverman (Your name here) gene therapy: new fund-raising gambit for family with rare disease The practice of honorary naming is unusual in the drug industry, but it shows the state of the market for rare disease therapies. By Jason Mast Adobe STAT+ | Novo Holdings is set to close its $16.5 billion acquisition of Catalent after FTC declines to challenge the deal Catalent is an attractive target for Novo Holdings because it is a subcontractor that already helps manufacture the obesity drug Wegovy. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser